Cognitive impairment (CI) in Multiple Sclerosis

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Cognitive impairment (CI) in Multiple Sclerosis"

Transcription

1 Multiple Sclerosis and Mild Cognitive Impairment What are the cognitive impairments in MS and why are the terms dementia and Mild Cognitive Impairment (MCI) rarely used? By Ronald Devere, MD Cognitive impairment (CI) in Multiple Sclerosis (MS) has been recognized for over 130 years since described by Charcot in the late nineteenth century. 1 He used the terms weakening of memory, slow conceptual thoughts and a blunted affect and intellectual life in his 1877 lectures. 1 The last 70 years have seen numerous papers published on this topic, partly due to improved neuropsychological testing, which is essential in evaluating CI. 2-4 Some degree of CI is common in MS. Using neuropsychological testing it affects upward of 45 percent of community dwelling populations. 4,5 Selfreported CI has been noted, not surprisingly, to be higher in up to 58 percent of the MS population in recent studies in Australia. 7,8 Summarizing the current status of cognitive impairment in MS is as follows: Cognitive impairment is relatively mild on neuropsychological testing in most people with MS. 9,10 The most common cognitive impairments involve complex attention, speed of processing information, short-term memory loss, complex visual-spatial processing, abstract reasoning, and problem solving. 9,10 Basic attention, routine social skills and general language skills, except mild word finding, are usually normal or mildly involved, even if other areas of cognition are more impaired. As a result of spared routine social and language skills, more cognitive impaired individuals can go undetected during brief or superficial social interactions. 9,10 Mini-mental testing (MMSE), the most frequently used office cognitive testing assessment, was mainly designed as a cognitive screen in the elderly and is being used regularly in the MS population. This test has been found to be very insensitive in detecting CI in MS and has been shown to miss severe neuropsychological proven CI in 20 percent of cases. 11 Patients with MS who are complaining of cognitive difficulties or are recognized by family and friends to have CI (memory loss, slow comprehension, and personality change), should undergo thorough neuropsychological evaluation to determine cognitive limitations, functional capacity, and emotional status. Duration of MS is generally considered a poor indicator of the presence of cognitive impairment. Severity of CI does not usually correlate with severity of MS. CI can be a significant symptom in up to 50 percent of recently diagnosed MS and has been well described in the clinically isolated syndrome 12,13 or initial presentation of disease. 14,15 Cognitive impairment does not correlate overall with physical impairment in this disease. 4,16 Cognitive impairment has not shown a consistent correlation with white matter burden on MRI. 5 However, this is changing because new MRI techniques can show cortical gray matter lesions not seen on routine MRI. Massimiliano et al. showed that cortical lesions on MRI obtained on double inversion recovery sequences and cortical atrophy strongly correlated with CI. 6 Future studies looking at cerebral cortical MS lesions may well change some of the current cognitive information in this disease. 26 Practical Neurology May/June 2011

2 Secondary progressive MS is an indicator of greater likelihood of CI. Chelune et al. 17 found that CI is seven times more likely in secondary progressive MS than in relapsing and remitting. Once CI becomes clinically apparent, it tends not to remit. The only exception is when it occurs solely as a temporary symptom during an exacerbation. This form is usually sudden in onset, coinciding with the onset of neurological physical symptoms and remits when the exacerbation is over. 18 Most studies have suggested a relative stability of cognitive impairment for up to four years. 19 Pirasm et al., 20 in a small sample of MS patients, showed that cognitive deterioration over an eight year period was limited to impaired long term memory and general intellectual function in fifty eight percent with relapsing, remitting MS. Other areas of cognitive function were very stable. Other studies have suggested a more predictable very slow decline, especially those with a progressive form of MS. 20 Overall, there is difficulty predicting change in a specific individual over time. Amato et al 5 concluded that cognitive deterioration in MS occurs much more slowly and less consistent than in Alzheimer s disease. This is an important point because cognitively impaired MS patients are likely to be stable enough or so slowly progress, that they have been shown to benefit significantly from cognitive rehabilitation Now that I have given some of the more important information on MS cognitive impairment, another important question is: How does CI really affect the quality of life (QOL) in MS patients? Most studies have been contradictory. 25,26 One recent study by Glanz et al. 27 using a standard cognitive evaluation and a self reported QOL questionnaire in early MS, with depression controlled, found that QOL was weak or negligibly related to cognitive function. A more recent study by Baumstark et al. 28 including all MS subtypes found the same conclusion. These studies stated that the key point in evaluating cognitive impairment and QOL in MS is recognizing that fatigue and depression need to be controlled, because they are independent predictors of QOL, regardless of the cognitive impairment. This point was stressed in past studies as well. 25,29,30 Pharmacological Treatment of Cognitive Impairment in MS Is there any evidence that specific medication is effective in cognitive impairment in MS? Greene et al. 31 studied Donepezil (Aricept) 10mg over a 12 week study in 17 MS cases. It showed statistically significant improvement in attention, memory, and executive function. Another double blind placebo randomized control study, 32 studied Donepezil (Aricept) for 24 weeks in 69 patients. There was significant improvement in memory, although the patients were only mildly impaired. One double blind random placebo controlled study 33 looked at Rivistigmine (Exelon) for 12 weeks in 60 cases and showed slight but significant improvement in memory in both patients and placebo group. The conclusion at this time is that the findings suggest some possible benefit of Donepezil, less so Rivistigmine, in MS cognitive impairment. More long-term studies of these and other medications (galantamine, memantine) are needed. There are a couple of points to consider regarding the above studies. Unlike Alzheimer s disease, there has been no solid pathological evidence that there is a deficiency of Acetylcholine in MS cognitive impairment. It has only been presumed based on the widespread demyelinating and axonal changes in MS plaques. This is not necessarily a reason not to try these medications in MS. Secondly, the patients enrolled in many of the above trials were not characterized as dementia or MCI and very little activities of daily living information were presented. This made it very difficult to decide what type of cognitive impaired patients were evaluated. In addition the trials were very short, lasting 12 to 24 weeks. We know from amnestic MCI studies, which were over a threeyear period, that possibly only Aricept might be of one to two year(s) benefit in delaying the development of AD. We also know from many studies that the cholinesterase and glutamate inhibitors have a modest effect on all stages of Alzheimer s disease. May/June 2011 Practical Neurology 27

3 Since the conclusion of all the MS studies have shown minimal or no benefit of these agents in cognitive impairment, these studies should be repeated with longer durations when proper cognitive classification is done. Dementia in MS Although the majority of patients with MS have mild cognitive changes, many develop more severe changes, as previously mentioned and warrant the use of the term dementia. Estimates of the rate of more severe cognitive impairment varies between five percent and 30 percent. 9,34,35 However, reviewing the titles and contents of many published articles on cognitive impairment in MS, it is surprising that the term dementia was rarely used and the concept of Mild Cognitive Impairment (MCI), which has become increasing popular over the last 15 years, is non-existent. A search for dementia in MS specifically yields a few articles. In one 36 publication, the author states: Determining a precise rate of occurrence of dementia in MS via review of the scientific literature is difficult, as the term, dementia and cognitive impairment are used interchangeably. Also other loosely defined terms such as global impairment or severe cognitive impairment are frequently used. The definition of dementia is currently undergoing changes because the old definition, published in DSM IV 1994, has become outdated in relationship to the increased information acquired about cognitive disorders and introduction of the term MCI in the last ten years. The Alzheimer s Association in 2010 proposed new updated criteria for Alzheimer Dementia and its relationship to MCI. These criteria have recently been adopted after a year review by several research groups and should be incorporated in the revised DSM criteria for dementia. The old DSM-IV criteria for dementia due to other medical conditions are: A. Development of multiple cognitive deficits: a. Memory impairment b. One or more of the following: aphasia, apraxia, agnosia, impaired executive function B. These deficits cause significant impairment in social or occupational function and represent a significant deterioration from the premorbid state C. Deficits are due to direct physiological consequences of a general medical condition (such as MS) D. Impairments do not occur as a result of delirium. It is important to note that the term progressive decline is not mentioned, since many of us know that most of the degenerative disorders like Alzheimer s disease, frontal dementia, Parkinson s and Lewy body dementia are progressive, unlike many MS moderate to severe cognitive impaired cases, which can remain stable for many years despite no specific cognitive treatments. MS cognitive impairment rarely develop major language impairment or impaired basic orientation. One study 4 found that MS dementia acted similar to a subcortical dementia like Parkinson s or Huntington s disease, which includes personality change, mood disturbances, slow thinking, decreased attention, problem solving and problems with memory retrieval. This was also echoed by others. 37 Others have stated that MS dementia is a form of frontal dementia. 38 One article published in 2005, 39 reported that nursing home residents with MS and dementia are usually admitted at an older age (10 years) than the non-demented MS patients and are less likely to have physical impairments but much more likely to have mood and behavioral problems. They suggested these cases may represent a cortical variant of MS characterized by progressive dementia and emotional difficulties with late onset of other neurological impairments leading to physical disability. Based on the excellent review by Longley 36 and this literature review, there are some possible reasons for the very infrequent use of the terms dementia and MCI in cognitive impaired MS patients. The term dementia in our society carries a terrible stigma of a progressive untreated cognitive deterioration, with strange and disturbing behavior, ending up in a nursing home to die. This term 28 Practical Neurology May/June 2011

4 has in general been used to apply to the older population and has led to very negative reactions in families and patients, because MS occurs in a much younger population and many who are more cognitively impaired usually articulate well and are capable of light social interaction. Patients with MS are usually in the early years of their careers, looking after young children and trying to work or run a household. With the help of their physician, they are also trying to manage a progressive or fluctuating degree of physical impairment. The sense of hope in the face of this unpredictable neurological disorder is very strong, not supported by the perceived term, dementia. The management and treatment of MS patients in the past 15 years has become very complicated and requires expert knowledge of the disease and its management. Numerous more potentially toxic medications with significant side effects are becoming more available. I am not sure how many general neurologists are treating these complicated patients, but more and more experts in clinical and research MS are available in private and university related practices. In my experience the majority of MS patients with cognitive disorders, regardless of severity, are regularly followed and treated by MS specialists and many general neurologists. The MS specialists are doing a lot of the clinical research and publishing many of the scientific papers. Their overall experience in using the terms MCI and dementia in their specialty practice may be limited. The cognitive testing in many published articles and in everyday practice of MS patients may or may not be done by neuropsychologists who are experts in the terminology of dementia and MCI. The term MCI has been recognized for over 10 years. 40 It has been predominantly used in the neurodegenerative pre-dementia arena, but the term is also being used in non-degenerative disorders like multiple strokes. 41 MCI is defined as a cognitive disorder with little or no impairment of activities of daily living, and stands between normal cognitive function and dementia. Any one or more areas of (impaired memory, executive function, speech/language, personality or visual perception) are acceptable under the category as long as they meet the strict definition of minimal-to-no-impairment of activities of daily living. Amnestic MCI has been shown to progress to AD in 75 percent of cases over a five-year period. Non-amnestic MCI has been shown to develop into AD in 55 percent, but other disorders like Parkinson s, Lewy body, frontal and multi-infarct dementia can develop in others. Some cases remain the same, never progress or rarely improve. In 2004, a study 41 divided amnestic and non-amnestic MCI into single or multiple domain. This was done, so all aspects of cognitive function were included (memory, executive function, speech, language, personality, and visual perception. This classification recognized that individuals with MCI may have more than one category of cognitive impairment, with no effect on ADLs and so they did not meet the criteria for a diagnosis of dementia. This information was important to document because multiple domain cognitive impairment was at times more likely to progress to dementia in a shorter time period. The dementia and MCI terminology have been very helpful in interpreting cognitive dysfunction, ADLs and quality of life, not only for research purposes but to counsel and educate patients and family about the disorder, in decisions on appointing a Durable Power of Attorney (DPOA), and making competent financial and estate decisions. Suggestions and advantages in incorporating cognitive abnormalities in MS into the mainstream of terminology used in other causes of cognitive impairment: Update clinical and research MS specialists and general neurologists in the terminology of dementia and MCI as it relates to MS and other causes of cognitive disorders especially Alzheimer s, Parkinson s, and frontal dementia and how they differ from MS dementia. This can be done in the various general and MS specialty journals or symposia on MS with assistance from members of the Cognitive and Behavioral section of the AAN. If not already done, reviews by the May/June 2011 Practical Neurology 29

5 legal system should be included in the same venues to discuss DPOA for health and estate decisions and legal guardianship and how it relates to cognitive impairment in the younger MS population. Since neuropsychological testing is so important in the diagnosis of cognitive dysfunction in MS, it is very important that the neuropsychologist, who is well trained in this terminology, be reminded that they should use this terminology in their summary and final opinion in their reports and help in education. It is also important that physical impairment not be included in impaired ADLs as it relates to cognitive impairment. Including physical impairment could under or over diagnose the cognitive effects on ADLs. For example, impaired memory in the presence of weak and numb arms could mistakenly be represented as inability to do finances and reconcile a check book for cognitive reasons. Memory impairment alone does not usually affect important financial and estate decisions, appointing a DPOA, and only mild cognitive supervision is normally necessary. MS patients, who meet the cognitive and ADL criteria for dementia, will likely require full time care and supervision and be unable to make decisions in their best interest regardless of the status of physical impairment. Thorough education is necessary to patients, families, other caregivers and MS societies, so they fully understand the terms dementia and MCI as it relates to MS. Attempts should also be made to erase some of the negative stigma or misunderstanding of the term dementia. Longley 36 stated a useful layman s definition of dementia for use with individuals with MS: It is a broad term to describe the loss of memory, thinking, some social skills and usually normal emotional reaction. It would also be very helpful to stress the significant difference in clinical presentation and progression over time, between MS dementia and Alzheimer s dementia. 36 The legal system should provide education to MS physicians, caregivers, patients and MS societies as relates to DPOA and legal guardianship. Careful, discrete, and appropriate use of the term dementia has been shown to be at times positive. This term stresses the severity of an individual s cognitive impairment. It can reduce the risk that the person s cognitive impairment may be dismissed because of their good initial presentation or because of their young age group. The proper use of the dementia term, where appropriate, can help the person obtain retirement benefits, a disability insurance claim, or help collect long-term care insurance if previously purchased. Summary and Conclusion The clinical knowledge relating to diagnosis and treatment of MS has mushroomed in the last 15 years. Cognitive impairment in MS has been well studied for many years and is briefly summarized in this review. Neurology still has a long way to go in pharmacological treatment to improve or arrest CI in MS. It is time to put cognitive abnormalities recognized in MS into a more common, defined classified terminology, such as dementia and MCI, instead of the general non-specific terms of cognitive impairment or global cognitive deterioration, so we can all better understand our patients cognitive impairment and capabilities as they relate to ADLs and make efforts to separate this from physical disability. The regular use of this terminology will require further education of patients, caregivers, MS societies, clinical and research MS specialists and non specialists who continue to treat this disorder. This information should be stressed in neurology residency training. It will require sensitivity and dispelling myths that are associated with these terms, especially dementia. Ronald Devere MD, FAAN, is Director of the Alzheimer s Disease and Memory Disorders Center in Austin, TX. 1. Charcot, J. M., Lectures On The Diseases Of The Nervous System, London: New Sydenham Society, Jambor, K. L., Cognitive Functioning In Multiple Sclerosis, British Journal of Psychiatry, 1969, Vol. 115, pp Rao, S. M., Neuropsychology Of Multiple Sclerosis: A Critical Review, 30 Practical Neurology May/June 2011

6 Journal of Clinical and Experimental Neuropsychology, 1986, Vol. 8, pp Rao, S. M., et al, Cognitive Dysfunction In Multiple Sclerosis: Frequency And Prediction, 1991, Vol. 41, pp Amato, M. P., Zipola, et al, Multiple Sclerosis Related Cognitive Changes: A Review Of Cross Sectional And Longitude Studies, Journal of Neurological Sciences, 2006, Vol. 245, pp Massimilliano, C., Cortical Lesions And Atrophy Associated With Relapsing And Remitting Multiple Sclerosis, Archives of Neurology, 2009; 66(9): Khan, F., et al, Disability Profile And Quality Of Life In An Australian Community, International Journal of Rehabilitation and Research, 2006, Vol. 29, pp Tribe, K., et al, Living With Multiple Sclerosis In New South Wales Australia At The Beginning Of The 21st Century: Impact Of Mobility And Disability, International Journal of Multiple Sclerosis Care, 2006, Vol. 8, pp Nocentini, U., et al, Cognitive Dysfunction In Patients With Relapsing And Remitting Multiple Sclerosis, 2006, Vol. 12, pp Wallen, M. T., et al, Cognitive Dysfunction In Multiple Sclerosis: Assessment, Imaging, And Risk Factors, Journal of Rehabilitation, Research and Development, 2006, Vol. 43, pp Beatty, W., et al, Implicit Learning In Patients With Chronic Progressive Multiple Sclerosis, International Journal of Clinical Neuropsychology, 1990, Vol. 12, pp Achron, A., et al, Cognitive Impairment In Probable Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry: 2003, Vol. 74, pp Amato, M. P., et al, Cognitive Disability In Early Onset Multiple Sclerosis: Pattern, Prediction And Impact On Every Day Life In A Four Year Follow-Up Study, Archives of Neurology: 1995, Vol. 52, pp Fontaine, B., et al, Dementia In Two Histology Confirmed Cases Of Multiple Sclerosis: One Case With An Isolated Dementia And One Case Associated With Psychiatric Symptoms, Journal of Neurology, Neurosurgery and Psychiatry: 1994, Vol. 57, pp Bunyan, R.F., et al, Childhood Onset Multiple Sclerosis With Progressive Dementia And Pathological Cortical Demyelination, Archives of Neurology: April 2011, Vol. 68, pp Peyser, J. M., et al, Cognitive Function In Patients With Multiple Sclerosis, Archives of Neurology: 1980, Vol. 37, pp Chelune, G. J., et al, Assessing The Prevalence And Relative Risk Of Cognitive Dysfunction In Patients With Multiple Sclerosis, J. Brain Impairment: 2004, Vol. 5 (Supplement), p Foong, J., et al, Neuropsychological Deficits In Multiple Sclerosis After Acute Relapse, Journal of Neurology, Neurosurgery and Psychiatry: 1998, Vol. 64, pp Jennekens-Schinkel, A., Cognition In Patients With Multiple Sclerosis, Journal of Neurosciences: 1990, Vol. 99, pp Pirasm, R., et al, Longitudinal Study Of Cognitive Dysfunction In Multiple Sclerosis: Neuropsychological, Neuroradiological, And Neurophysiological Findings, Journal of Neurology, Neurosurgery and Psychiatry: 2003, Vol. 74, pp Kajula, P., et al, Progress Of Decline In Multiple Sclerosis: A Controlled Three-Year Study, Journal of Brain: 1997, Vol. 120, pp Baker, N.A., et al, The Effectiveness Of Physical And Psychological Functional Intervention In Treating Clients With Multiple Sclerosis: A Meta- Analysis, American Journal of Occupational Therapy: 2001, Vol. 55, pp Patti, F., et al, Effects Of A Short Outpatient Rehabilitation Treatment On Disability Of Multiple Sclerosis Patients, Journal of Neurology: 2003, Vol. 250, pp Lincoln, N.B., et al, Treatment Of Cognitive Problems For People With Multiple Sclerosis, International Journal of Therapy and Rehabilitation: 2003, Vol. 10, pp Lovera, J., et al, Correlations Of Perceived Deficits Questionnaire Of Multiple Sclerosis Quality Of Life Inventory With Beck Depression Inventory And Neuropsychological Test, Journal of Rehabilitation, Research and Development: 2006, Vol. 43, pp Gold, S.M., et al, Cognitive Impairment In Multiple Sclerosis Does Not Effect Reliability And Validity Of Self-Report Health Measures, J. Multiple Sclerosis: 2003, Vol. 9, pp Glanz, B. I., et al, The Association Between Cognitive Impairment And Quality Of Life In Patients With Early Multiple Sclerosis, Journal of Neurological Sciences: 2009, Vol. 290, pp Baumstarck-Barrau, K., et al, Cognitive Function And Quality Of Life In Multiple Sclerosis, BMC Neurology: 2001, Vol. 11, p Mitchell, A. J., et al, Quality Of Life And Its Assessment In Multiple Sclerosis: Intergrading Physical And Psychological Components Of Well-Being, Lancet Neurology: 2005, Vol. 231, pp Janardhan, V., et al, Quality Of Life In Patients With Multiple Sclerosis: The Impact Of Fatigue And Depression, Journal of Neurological Sciences: 2002, Vol. 205, pp Greene, Yin, et al, Twelve-Week Open Trial Of Donepezil With Patients With Multiple Sclerosis And Associated Cognitive Impairments, Journal of Clinical Psycho-pharmacology: 2000, Vol. 20, pp Krupp, L. B., et al, Donepezil Improved Memory In Multiple Sclerosis In A Randomized Clinical Trial, Neurology: 2004,Vol. 63, p Shaygannejad, V., et al, Effects Of Rivastigmine On Memory And Cognition In Multiple Sclerosis Patients, Canadian Journal of Neurological Sciences: 2008, Vol. 35, pp Fischer, J. S., et al, Heterogeneity Of Cognitive Dysfunction In Multiple Sclerosis, Journal of The Clinical Neuropsychologist: 1998, Vol. 12, p Raw, S. M., White Matter Disease In Dementia, Brain and Cognition, 1966, Vol. 31, pp Longley, W. A., Multiple Sclerosis Related Dementia, Relatively Rare And Often Misunderstood, Brain Impairment, Vol. 8 (2), September 2007, pp Schmidt, R., et al, Subcortical Vascular Cognitive Impairment: Simulating Similarities And Differences With Multiple Sclerosis, Journal of Neurological Sciences: 2006, Vol. 245, pp Comi, G., et al, A Multi-Parametric MRI Study Of Frontal Lobe Dementia In Multiple Sclerosis, Journal of Neurological Sciences: 1999, Vol. 71(2), pp Buchanan, R. J., et al, Nursing Home Residents With Multiple Sclerosis And Dementia Compared To Other Multiple Sclerosis Residents, Journal of Multiple Sclerosis: October 11, 2005 (5), pp Peterson, R. C., et al, Mild Cognitive Impairment, Clinical Characterization And Outcome, Archives of Neurology: March 1999, Vol. 56, pp Peterson, R. C., et al, Mild Cognitive Impairment As A Diagnostic Entity, Journal of Internal Medicine: September 2004, Vol. 256 (3), pp Bamford, C., et al, Disclosing A Diagnosis Of Dementia: A Systematic Review, International Journal of Geriatric Psychiatry: 2010, Vol. 19, pp May/June 2011 Practical Neurology 31

Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.

Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych. Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych. Community Geriatric Mental Health Model of Continuum of Cognition with Aging Normal Mild cognitive

More information

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate

More information

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia

More information

Alzheimer's: The Latest Assessment and Treatment Strategies

Alzheimer's: The Latest Assessment and Treatment Strategies Questions from chapter 1 Alzheimer's: The Latest Assessment and Treatment Strategies 1) What is a loss of cognitive and intellectual powers without changes in consciousness. a) dementia b) delusions c)

More information

Primary Endpoints in Alzheimer s Dementia

Primary Endpoints in Alzheimer s Dementia Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in

More information

Summary chapter 2 chapter 2

Summary chapter 2 chapter 2 Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological

More information

1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136. Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) 355 9028 (JMH, Downtown)

1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136. Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) 355 9028 (JMH, Downtown) UNIVERSITY OF MIAMI, LEONARD M. MILLER SCHOOL OF MEDICINE CLINICAL NEUROPSYCHOLOGY UHEALTH PSYCHIATRY AT MENTAL HEALTH HOSPITAL CENTER 1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136 Days and Hours:

More information

Diagnosis and Initial Management of Cognitive Disorders

Diagnosis and Initial Management of Cognitive Disorders Diagnosis and Initial Management of Cognitive Disorders January 29, 2016 Kelly Garrett, PhD Cathleen Obray, MD, MHS Neurosciences Clinical Program Cognitive Care Team None Disclosures Neurosciences Clinical

More information

REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD

REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD What is Rehabilitation Medicine? Rehabilitation Medicine (RM) is the medical specialty with rehabilitation as its primary strategy. It provides services

More information

Emergency Room Treatment of Psychosis

Emergency Room Treatment of Psychosis OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

More information

2016 CODING FOR FETAL ALCOHOL SPECTRUM DISORDERS

2016 CODING FOR FETAL ALCOHOL SPECTRUM DISORDERS 2016 CODING FOR FETAL ALCOHOL SPECTRUM DISORDERS Listed below are the most commonly used codes applicable to FASD patient care. Code Description ICD-10-CM Primary Diagnosis P04.3 Newborn (suspected to

More information

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment Dementia David Lam, MD, FRCPC, Psychiatry Assistant Clinical Professor Department of Psychiatry and Behavioural Neurosciences McMaster University Hamilton, Ontario Objectives Aging and Forgetfulness Define

More information

Dementia: Delivering the Diagnosis

Dementia: Delivering the Diagnosis Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology University of Utah Diagnosing Dementia

More information

The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia

The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia By Scott Knight, Director, SLR Diagnostics & Assessments, a division of Sibley & Associates Inc., and Konstantine

More information

Mellen Center Approaches: Identifying and managing cognitive disorders in MS

Mellen Center Approaches: Identifying and managing cognitive disorders in MS Mellen Center Approaches: Identifying and managing cognitive disorders in MS Framework: Cognitive dysfunction is common in the MS population. It affects quality of life and correlates with worsened disease

More information

Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca

Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca Mental health issues in the elderly January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca Cognitive Disorders Outline Dementia (294.xx) Dementia of the Alzheimer's Type (early and late

More information

What is vascular dementia?

What is vascular dementia? alzheimers.org.uk What is vascular dementia? Vascular dementia is the second most common form of dementia after Alzheimer s disease. It is caused by problems in the supply of blood to the brain. This factsheet

More information

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease. Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease. Memory loss and changes in mood and behavior are some signs that you or a family member may have Alzheimer s disease. If you have

More information

Behavioral Health Psychological/Neuropsychological Testing Guidelines

Behavioral Health Psychological/Neuropsychological Testing Guidelines Behavioral Health Psychological/Neuropsychological Testing Guidelines Psychological testing (procedural code 96101) and Neuropsychological Testing (procedural code 96118) involve the culturally and linguistically

More information

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease 2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,

More information

Update on Treatment of the Dementias

Update on Treatment of the Dementias Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label

More information

Guidelines for Medical Necessity Determination for Occupational Therapy

Guidelines for Medical Necessity Determination for Occupational Therapy Guidelines for Medical Necessity Determination for Occupational Therapy These Guidelines for Medical Necessity Determination (Guidelines) identify the clinical information MassHealth needs to determine

More information

Psychological and Neuropsychological Testing

Psychological and Neuropsychological Testing 2015 Level of Care Guidelines Psych & Neuropsych Testing Psychological and Neuropsychological Testing Introduction: The Psychological and Neuropsychological Testing Guidelines provide objective and evidencebased

More information

2016 Programs & Information

2016 Programs & Information Mayo Alzheimer s Disease Research Clinic Education Center 2016 Programs & Information BROCHURE TITLE FLUSH RIGHT for Persons & Families impacted by Mild Cognitive Impairment Alzheimer s Disease Dementia

More information

FUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov

FUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov FUNCTIONAL EEG ANALYZE IN AUTISM Dr. Plamen Dimitrov Preamble Autism or Autistic Spectrum Disorders (ASD) is a mental developmental disorder, manifested in the early childhood and is characterized by qualitative

More information

MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION

MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION Michael K. Racke, MD Professor and Chairman in Neurology The Helen C. Kurtz Chair in Neurology Department of Neurology Ohio State University

More information

Social Security Disability Insurance and young onset dementia: A guide for employers and employees

Social Security Disability Insurance and young onset dementia: A guide for employers and employees Social Security Disability Insurance and young onset dementia: A guide for employers and employees What is Social Security Disability Insurance? Social Security Disability Insurance (SSDI) is a payroll

More information

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE 1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff

More information

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive

More information

CRITERIA FOR AD DEMENTIA June 11, 2010

CRITERIA FOR AD DEMENTIA June 11, 2010 CRITERIA F AD DEMENTIA June 11, 2010 Alzheimer s Disease Dementia Workgroup Guy McKhann, Johns Hopkins University (Chair) Bradley Hyman, Massachusetts General Hospital Clifford Jack, Mayo Clinic Rochester

More information

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015 Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015 Introduction Wellness and the strategies needed to achieve it is a high priority

More information

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015 The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

More information

Objectives. Evaluation of Memory Loss. Cognitive Impairment. Clinical Questions. Medicare Wellness Visit

Objectives. Evaluation of Memory Loss. Cognitive Impairment. Clinical Questions. Medicare Wellness Visit Evaluation of Memory Loss and Mild Cognitive Impairment Skotti Church, MD Geriatrics Grand Rounds 4/3/2014 Objectives 1. Describe recommendations and tools for evaluation of cognitive impairment 2. Define

More information

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families Understanding Relapse in Multiple Sclerosis A guide for people with MS and their families Introduction You have been given this booklet because you have been diagnosed with Multiple Sclerosis (MS) and

More information

Cognitive Testing for Underwriting Life Insurance

Cognitive Testing for Underwriting Life Insurance Cognitive Testing for Underwriting Life Insurance Presentation to the Mortality Working Group of the International Actuarial Association Al Klein April 8, 2011 Cognitive function Agenda What is it? What

More information

Chapter 10. Summary & Future perspectives

Chapter 10. Summary & Future perspectives Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral

More information

LONG TERM CARE INSURANCE OUTLINE OF COVERAGE FOR EMPLOYEES OF. FLORIDA INSTITUTE OF TECHNOLOGY (the Sponsoring Organization)

LONG TERM CARE INSURANCE OUTLINE OF COVERAGE FOR EMPLOYEES OF. FLORIDA INSTITUTE OF TECHNOLOGY (the Sponsoring Organization) UNUM Life Insurance Company of America 2211 Congress Street Portland, Maine 04122 (207) 575-2211 LONG TERM CARE INSURANCE OUTLINE OF COVERAGE FOR EMPLOYEES OF FLORIDA INSTITUTE OF TECHNOLOGY (the Sponsoring

More information

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease Understanding NICE guidance Information for people who use NHS services Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease NICE technology appraisal guidance advises on when and

More information

TCHP Behavioral Health Psychological/Neuropsychological Testing Child/Adolescent Guidelines

TCHP Behavioral Health Psychological/Neuropsychological Testing Child/Adolescent Guidelines TCHP Behavioral Health Psychological/Neuropsychological Testing Child/Adolescent Guidelines Psychological testing involves the culturally and linguistically competent administration and interpretation

More information

Staging and Treatment of Dementia

Staging and Treatment of Dementia Staging and Treatment of Dementia Ami Hall DO 10/25/14 1 Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available Definition

More information

Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management

Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management Eastern Health Multiple Sclerosis Nurse Practitioner Service Model April 2014 Prepared by Jodi Haartsen and Deanna

More information

The lifetime prevalence of depression in patients with MS is approximately 1

The lifetime prevalence of depression in patients with MS is approximately 1 Rebecca M. Floyd, Ph.D., Kimberly Lewis, Ph.D., Eliot Lopez, M.S., Thomas Toomey, B.A., Kena Arnold, B.A., and Lara Stepleman, Ph.D. The lifetime prevalence of depression in patients with MS is approximately

More information

Alzheimer s and Depression: What is the Connection?

Alzheimer s and Depression: What is the Connection? Alzheimer s and Depression: What is the Connection? Ladson Hinton MD Professor and Director of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Director, Education Core, Alzheimer

More information

Stephen L. Benson, Psy.D. November 17, 2015

Stephen L. Benson, Psy.D. November 17, 2015 Stephen L. Benson, Psy.D. November 17, 2015 Biomedical view of dementia Lyman (1989) suggested that the biomedical view of dementia includes three features: First, dementia is pathological and individual,

More information

The Psychologists Board of Western Australia

The Psychologists Board of Western Australia The Psychologists Board of Western Australia APPLICANT S PROGRAMME - CLINICAL NEUROPSYCHOLOGY and Knowledge INTRODUCTION Psychologists entering supervision for registration of the specialist title, Clinical

More information

Epilepsy and Neuropsychology Dr. Sare Akdag, RPsych

Epilepsy and Neuropsychology Dr. Sare Akdag, RPsych Epilepsy and Neuropsychology Dr. Sare Akdag, RPsych Most people living with epilepsy do not experience serious problems with their thinking. However, there are aspects of thinking that can be affected

More information

Cognitive Rehabilitation for Executive Dysfunction in Parkinson s Disease

Cognitive Rehabilitation for Executive Dysfunction in Parkinson s Disease Calleo, J., Burrows, C., Levin, H., Marsh, L., Lai, E., York, M. (2012). Cognitive rehabilitation for executive dysfunction in Parkinson s disease: application and current directions., vol. 2012, Article

More information

PSYC PSYCHOLOGY. 2011-2012 Calendar Proof

PSYC PSYCHOLOGY. 2011-2012 Calendar Proof PSYC PSYCHOLOGY PSYC1003 is a prerequisite for PSYC1004 and PSYC1004 is a prerequisite for all remaining Psychology courses. Note: See beginning of Section F for abbreviations, course numbers and coding.

More information

Intellectual Symptoms Amnesia: Loss of memory function

Intellectual Symptoms Amnesia: Loss of memory function Definition of Dementia (de mens) Latin for out of mind Permanent loss of multiple intellectual functions Alois Alzheimer first described this disease in 1906 in a brain specimen from an autopsy. Alzheimer

More information

Response from Neurobehaviour Clinic at National Rehabilitation Hospital to Submission to Second Independent Monitoring Group: A Vision for Change

Response from Neurobehaviour Clinic at National Rehabilitation Hospital to Submission to Second Independent Monitoring Group: A Vision for Change November 30 2009: Page 1 of 5 Response from Neurobehaviour Clinic at National Rehabilitation Hospital to Submission to Second Independent Monitoring Group: A Vision for Change Prepared by: Dr. Simone Carton,

More information

COURSE APPROVAL GUIDELINES APS COLLEGE OF CLINICAL NEUROPSYCHOLOGISTS

COURSE APPROVAL GUIDELINES APS COLLEGE OF CLINICAL NEUROPSYCHOLOGISTS Page 1 COURSE APPROVAL GUIDELINES APS COLLEGE OF CLINICAL NEUROPSYCHOLOGISTS Updated October 2000 Page 2 1. General Introduction and Principles Clinical neuropsychology is a division of psychology concerned

More information

Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi.

Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi. Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi. Suresh Kumar, M.D. AUTHOR Director of: Neurology & Headaches Center Inc. Neurocognitve &TBI Rehabilitation Center

More information

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine) 1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s

More information

Psychological and Neuropsychological Testing

Psychological and Neuropsychological Testing Psychological and Neuropsychological Testing I. Policy University Health Alliance (UHA) will reimburse for Psychological and Neuropsychological Testing (PT/NPT) when it is determined to be medically necessary

More information

Guidelines for Medical Necessity Determination for Speech and Language Therapy

Guidelines for Medical Necessity Determination for Speech and Language Therapy Guidelines for Medical Necessity Determination for Speech and Language Therapy These Guidelines for Medical Necessity Determination (Guidelines) identify the clinical information MassHealth needs to determine

More information

PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING

PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING Status Active Medical and Behavioral Health Policy Section: Behavioral Health Policy Number: X-45 Effective Date: 01/22/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Cognitive rehabilitation in MS

Cognitive rehabilitation in MS 14th MS Nurse International Workshop Lyon, France, October 9th 2012 Cognitive and psychological issues in MS Cognitive rehabilitation in MS Psychological Unit Neurological Department San Raffaele Hospital

More information

MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease Outline of Today s Lecture Why is Alzheimer s disease a problem? What is Alzheimer s Disease? What causes Alzheimer s disease? How can

More information

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Cycle C June 2, 2015 1 Introduction The landscape for the treatment of relapsing Multiple Sclerosis (MS) has quickly evolved over

More information

TESTING GUIDELINES PerformCare: HealthChoices. Guidelines for Psychological Testing

TESTING GUIDELINES PerformCare: HealthChoices. Guidelines for Psychological Testing TESTING GUIDELINES PerformCare: HealthChoices Guidelines for Psychological Testing Testing of personality characteristics, symptom levels, intellectual level or functional capacity is sometimes medically

More information

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,

More information

Integrated Neuropsychological Assessment

Integrated Neuropsychological Assessment Integrated Neuropsychological Assessment Dr. Diana Velikonja C.Psych Neuropsychology, Hamilton Health Sciences, ABI Program Assistant Professor, Psychiatry and Behavioural Neurosciences Faculty of Health

More information

OHTAC Recommendation

OHTAC Recommendation OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the

More information

Thomas R. Wodushek, Ph.D., ABPP-CN

Thomas R. Wodushek, Ph.D., ABPP-CN Curriculum Vitae Personal contact information: 2450 Windrow Dr. #E-201 wodushek@hotmail.com Fort Collins, CO 80525 970-689-2152 Practice Location:, P.C. Fort Collins, CO 80524 BOARD CERTIFICATION IN CLINICAL

More information

Dedicated Stroke Interprofessional Rehab Team. Mixed Rehab Unit. Dedicated Rehab Unit

Dedicated Stroke Interprofessional Rehab Team. Mixed Rehab Unit. Dedicated Rehab Unit Outpatient & Community I n p a t I e n t Stroke Rehab Definition Framework Institutional Setting Inpatient Rehab in Acute Care or Rehab Hospitals* Acute Care Integrated Specialized Units Transitional Care

More information

How to identify, approach and assist employees with young onset dementia: A guide for employers

How to identify, approach and assist employees with young onset dementia: A guide for employers How to identify, approach and assist employees with young onset dementia: A guide for employers What is dementia? Dementia involves the decline of cognitive functions. Young Onset Dementia, also known

More information

Patients with dementia and other types of structural brain injury are predisposed to delirium (i.e., abrupt onset, temporary confusion caused by

Patients with dementia and other types of structural brain injury are predisposed to delirium (i.e., abrupt onset, temporary confusion caused by Dementia is the permanent loss of multiple intellectual functions resulting from neuronal death. Dementia afflicts 10% of individuals over the age of 65 and these patients survive approximately seven years

More information

Tinnitus: a brief overview

Tinnitus: a brief overview : a brief overview sufferers experience sound in the absence of an external source. Sounds heard in tinnitus tend to be buzzing, hissing or ringing rather than fully-formed sounds such as speech or music.

More information

Epilepsy 101: Getting Started

Epilepsy 101: Getting Started American Epilepsy Society 1 Epilepsy 101 for nurses has been developed by the American Epilepsy Society to prepare professional nurses to understand the general issues, concerns and needs of people with

More information

Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI)

Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI) Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI) Mike R. Schoenberg, PhD, ABPP-CN Diplomate, American Board of Clinical Neuropsychology Licensed Psychologist Departments of Psychiatry

More information

PARTNERING WITH YOUR DOCTOR:

PARTNERING WITH YOUR DOCTOR: PARTNERING WITH YOUR DOCTOR: A Guide for Persons with Memory Problems and Their Care Partners Alzheimer s Association Table of Contents PARTNERING WITH YOUR DOCTOR: When is Memory Loss a Problem? 2 What

More information

Alzheimer s disease. The importance of early diagnosis

Alzheimer s disease. The importance of early diagnosis Alzheimer s disease The importance of early diagnosis Key Facts Alzheimer s disease and other dementias 1 Alzheimer's disease is the leading form of dementia and accounts for 50%-75% of all cases. 1 Vascular

More information

1: Motor neurone disease (MND)

1: Motor neurone disease (MND) 1: Motor neurone disease (MND) This section provides basic facts about motor neurone disease (MND) and its diagnosis. The following information is an extracted section from our full guide Living with motor

More information

Traumatic brain injury (TBI)

Traumatic brain injury (TBI) Traumatic brain injury (TBI) A topic in the Alzheimer s Association series on understanding dementia. About dementia Dementia is a condition in which a person has significant difficulty with daily functioning

More information

Early Childhood Measurement and Evaluation Tool Review

Early Childhood Measurement and Evaluation Tool Review Early Childhood Measurement and Evaluation Tool Review Early Childhood Measurement and Evaluation (ECME), a portfolio within CUP, produces Early Childhood Measurement Tool Reviews as a resource for those

More information

Comprehensive Special Education Plan. Programs and Services for Students with Disabilities

Comprehensive Special Education Plan. Programs and Services for Students with Disabilities Comprehensive Special Education Plan Programs and Services for Students with Disabilities The Pupil Personnel Services of the Corning-Painted Post Area School District is dedicated to work collaboratively

More information

See also www.thiswayup.org.au/clinic for an online treatment course.

See also www.thiswayup.org.au/clinic for an online treatment course. Depression What is depression? Depression is one of the common human emotional states. It is common to experience feelings of sadness and tiredness in response to life events, such as losses or disappointments.

More information

NAVIGATING THE MEDICARE MAZE OF REHABILITATIVE SERVICES

NAVIGATING THE MEDICARE MAZE OF REHABILITATIVE SERVICES NAVIGATING THE MEDICARE MAZE OF REHABILITATIVE SERVICES NAVIGATING THE COMPLEXITY OF INSURANCE COVERAGE. Fox Rehabilitation is a private practice of physical, occupational, and speech therapists who specialize

More information

Dementia Causes and Neuropsychological Evaluation of the Older Adult

Dementia Causes and Neuropsychological Evaluation of the Older Adult Dementia Causes and Neuropsychological Evaluation of the Older Adult Laurie N. Culp, Ph.D. Pate and Culp Psychological Assoc. 2440 Lawrenceville Highway Suite 200 Decatur, GA 30033 678-595-0062 lculp@emory.edu

More information

Managing depression after stroke. Presented by Maree Hackett

Managing depression after stroke. Presented by Maree Hackett Managing depression after stroke Presented by Maree Hackett After stroke Physical changes We can see these Depression Emotionalism Anxiety Confusion Communication problems What is depression? Category

More information

OhioHealth Neuroscience

OhioHealth Neuroscience SEPTEMBER/OCTOBER 2013 OhioHealth Neuroscience CLINICAL UPDATE IN THIS ISSUE: NEW SERVICES OhioHealth advancing many of its programs across the neuroscience continuum of care NEW FACILITY OhioHealth Rehabilitaton

More information

Trauma Insurance Claims Seminar Invitation

Trauma Insurance Claims Seminar Invitation Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims

More information

Early Response Concussion Recovery

Early Response Concussion Recovery Early Response Concussion Recovery KRISTA MAILEY, BSW RSW, CONCUSSION RECOVERY CONSULTANT CAREY MINTZ, PH.D., C. PSYCH., PRACTICE IN CLINICAL NEUROPSYCHOLOGY FOR REFERRAL: Contact Krista Mailey at (204)

More information

PARTNERSHIP HEALTHPLAN OF CALIFORNIA POLICY / PROCEDURE:

PARTNERSHIP HEALTHPLAN OF CALIFORNIA POLICY / PROCEDURE: PARTNERSHIP HEALTHPLAN OF CALIFORNIA POLICY/PROCEDURE Policy Number: MCUP3003 (previously UP100303) Reviewing Entities: Credentialing IQI P & T QUAC Approving Entities: BOARD CEO COMPLIANCE FINANCE PAC

More information

Understanding Relapse in Multiple Sclerosis

Understanding Relapse in Multiple Sclerosis Understanding Relapse in Multiple Sclerosis A guide for people with MS and their families Introduction Relapses are very common in MS and largely unpredictable in terms of how often they occur, how severe

More information

Collaborative Care for Alzheimer s Disease

Collaborative Care for Alzheimer s Disease The Health Care Workforce for Older Americans: Promoting Team Care Institute of Medicine Symposium October 2008 Collaborative Care for Alzheimer s Disease Christopher M. Callahan, MD Cornelius and Yvonne

More information

Donna Graves, M.D. Assistant Professor University of Texas Southwestern Multiple Sclerosis Clinic

Donna Graves, M.D. Assistant Professor University of Texas Southwestern Multiple Sclerosis Clinic Donna Graves, M.D. Assistant Professor University of Texas Southwestern Multiple Sclerosis Clinic I have received honoraria from Teva pharmaceuticals, Novartis, and Bayer pharmaceuticals. Obtaining CME

More information

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James

More information

Depression & Multiple Sclerosis

Depression & Multiple Sclerosis Depression & Multiple Sclerosis Managing specific issues Aaron, diagnosed in 1995. The words depressed and depression are used so casually in everyday conversation that their meaning has become murky.

More information

Everyone has mild memory lapses from time to time. You go

Everyone has mild memory lapses from time to time. You go Coping With Memory Loss Everyone has mild memory lapses from time to time. You go from the kitchen to the bedroom to get something, only to find yourself wondering what you needed. You can t find your

More information

Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS)

Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS) ETMIS 2012; Vol. 8: N o 7 Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS) March 2012 A production of the Institut national d

More information

Documentation Guidelines for ADD/ADHD

Documentation Guidelines for ADD/ADHD Documentation Guidelines for ADD/ADHD Hope College Academic Success Center This document was developed following the best practice recommendations for disability documentation as outlined by the Association

More information

Overview. Neuropsychological Assessment in Stroke. Why a Neuropsychologist. How to make a referral. Referral Questions 11/6/2013

Overview. Neuropsychological Assessment in Stroke. Why a Neuropsychologist. How to make a referral. Referral Questions 11/6/2013 Overview Neuropsychological Assessment in Stroke Brandon Ally, PhD Department of Neurology What is Neuropsychology Stroke Specific Neuropsychology Neuropsychological Domains Case Study What is Neuropsychology?

More information

Community Network for Dementia and Critical Path in Japan

Community Network for Dementia and Critical Path in Japan Research and Reviews Community Network for Dementia and Critical Path in Japan JMAJ 54(5): 305 309, 2011 Satoshi ORIMO* 1 Abstract In Setagaya City of Tokyo, regional hospitals and medical associations

More information

Why study clinical neuropsychology?

Why study clinical neuropsychology? University Leiden, The Netherlands Master (MSc) in Clinical Neuropsychology H.A.M.Middelkoop@lumc.nl www.neuropsychologie.leidenuniv.nl Why study clinical neuropsychology? You are interested in: brain/behavior

More information

The Handbook of Clinical Neuropsychology

The Handbook of Clinical Neuropsychology Oxford Scholarship Online You are looking at 1-10 of 44 items for: keywords : Church of God psyclin psyneu The Handbook of Clinical Neuropsychology John Marshall Jennifer Gurd and Udo Kischka (eds) Item

More information

Mellen Center for Multiple Sclerosis

Mellen Center for Multiple Sclerosis Mellen Center Cleveland Clinic Marie Namey, RN, MSN, MSCN Mellen Center Cleveland Clinic Cleveland, OH Home of. Mellen Center for Multiple Sclerosis Mellen Center Mission The Mellen Center remains committed

More information

Acquired dyslexia as conversion disorder: Identification and management. Introduction. Case Description

Acquired dyslexia as conversion disorder: Identification and management. Introduction. Case Description Introduction Acquired dyslexia in previously literate adults is most commonly the outcome of one of a variety of neuropathologies including dementia, stroke, neoplasm, multiple sclerosis, and migraine

More information

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

Prescribing Framework for Donepezil in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP

More information

Post-Acute Rehab: Community Re-Entry After Stroke? Sheldon Herring, Ph.D. Roger C. Peace Rehab Hospital Greenville Hospital System

Post-Acute Rehab: Community Re-Entry After Stroke? Sheldon Herring, Ph.D. Roger C. Peace Rehab Hospital Greenville Hospital System Post-Acute Rehab: Community Re-Entry After Stroke? Sheldon Herring, Ph.D. Roger C. Peace Rehab Hospital Greenville Hospital System 2014 Neurocognitive Deficits After Stroke: The Hidden Disability Sheldon

More information